Inhaled glucocorticoids and adrenal function: An update

Paediatric Respiratory Reviews

Volumn 4, Issue 2, 2003, Pages 153-161

  Crowley, Suzanne ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Adrenal failure; Asthma; Children; Growth failure; Inhaled glucocorticoids; Systemic effects

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOTROPIN; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; PREDNISOLONE;

ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ASTHMA; BINDING AFFINITY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; INSULIN TOLERANCE TEST; LIVER METABOLISM; MOLECULAR MECHANICS; MORBIDITY; PRIORITY JOURNAL; REVIEW;

EID: 0038617756     PISSN: 15260550     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-0542(03)00029-0     Document Type: Review

References (70)

1. Lanes SF, Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 683-686.
2. Blais L, Ernst P, Boivin J-F, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998; 158: 126-132.
3. Dickson W, Hall CE, Ellis M, Horrocks RH. Beclomethasone dipropionate aerosol in childhood asthma. Arch Dis Child 1973; 48: 671-675.
4. Law CM, Marchant JL, Honour JW, Preece MA, Warner JO. Noctumal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet 1986; i: 942-944.
5. Vaz R, Senior B, Morris M, Binkiewicz A. Adrenal effects of beclomethasone inhalation therapy in asthmatic children. J Pediart 1982; 100: 660-662.
6. Wyatt R, Waschek J, Weinberger M, Sherman B. Effects of inhaled beclomethasone dipropionate and alternate-day prednisolone on pituitary-adrenal function in children with chronic asthma. N Engl J Med 1978; 299: 1387-1392.
7. Mellis CM, Phelan PD. Asthma deaths in children - a continuing problem. Thorax 1977; 32: 29-34.
8. The British Guidelines on Asthma Management. 1995 Review and Position Statement. Thorax 1997; 52(supplement 1): S1-S21.
9. Russell G. Inhaled corticosteroids and adrenal insufficiency. Arch Dis Child 2002; 87: 455-456.
10. CSM/MCA. Current problems in pharmacovigilance. 2001; 28: 7.
11. Russell G. On observational studies on growth effects of inhaled cortcosteroids in asthma. Pediatr Pulmonol 1999; 27: 294-296.
12. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-572.
13. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000; 55: 603-613.
14. Meyer T, Carlstedt-Duke J, Meyer T, Starr D. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem 1997; 272: 30709-30714.
15. Phillips A, Maira M, Mullick A et al. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol 1997; 17: 5952-5959.
16. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones - a focus on rapid, non-genomic effects. Pharmacol Rev 2000; 52: 513-555.
17. Falkenstein F, Norman AW, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 2000; 85: 2072-2075.
18. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002; 67: 529-534.
19. Borski RJ, Hyde GN, Fruchtman S. Signal transduction mechanisms mediating rapid, non-genomic effects of cortisol on prolactin release. Steroids 2002: 67: 339-548.
20. Jaffuel D, Demoly P, Gougat C et al. Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 2000; 162: 57-63.
21. Jaffuel D, Roumestan C, Balaguer P et al. Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids. Steroids 2001; 66: 597-604.
22. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-κB and lack of I-κB involvement, Br J Pharmacol 1999; 127: 1003-1011.
23. Derendorf H, Hochhaus G, Meibohm B, Mollman H. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1997; 101: S440-S446.
24. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975; 51 (supplement 4): 20-25.
25. Andersson P, Ryrefeldt A, Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17α,21-monopropionate in human liver and lung homogenate. J Pharm Pharmacol 1984; 36: 763-765.
26. Crim C, Pierre LN, Daley-Yates PT. A Review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Therapeut 2002; 23: 1339-1354.
27. Brutsche MH, Brutsche IC, Munawar M et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556-561.
28. Anhoj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000; 162: 1819-1822.
29. Soldan M, Nagel G, Losekam M, Ernst M, Maser E. Interindividual variability in the expression and NNK carponyl reductase activity of II beta-hydroxysteroid dehydrogenase I in human lung. Cancer Lett 1999; 145: 49-56.
30. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P, Stewart PM. Absence of Cushingoid phenotype in a patient with Cushing's disease due to a defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87: 57-62.
31. Orsida BE, Krozowski ZS, Walters EH. Clinical relevance of airway II β-hydroxysteroid dehydrogenase type II enzyme in asthma. Am J Respir Crit Care Med 2002; 165: 1010-1014.
32. Schleimer RP. Potential regulation of inflammation in the lung by local metabolism of hydrocortisone. Am J Respir Cell Met Biol 1991; 4: 166-173.
33. Panarelli M, Holloway CD, Fraser R et al. Glucocorticoid receptor polymorphism, skin vasoconstirction, and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab 1998; 83: 1846-1852.
34. De Lange P, Koper JW, Huizenga ATM et al. Differential hormone-dependent transcriptional activation and repression by naturally occurring human glucocorticoid receptor variants. Mol Endocrinol 1997; 11: 1156-1164.
35. Huizenga NA, Koper JW, De Lange P et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144-151.
36. Parker LN. Adrenarche and puberty. In: Adrenal Androgens in Clinical Medicine, California: Academic Press, 1989; 11.
37. Hennebold JD, Daynes RA. Regulation of macrophage dehydroepiandrosterone sulphate by inflammatory cytokines. Endocrinology 1994; 135: 67-75.
38. Sudo N, Yu XN, Kubo C. Dehydroepiandrosterone attenuates the spontaneous elevation of serum IgE level in NC/Nga mice. Immunol Lett 2001; 79: 177-179.
39. Ledochowski M, Murr C, Jager M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. Exp Gerontol 2001; 36: 1739-1747.
40. Barrett-Connor F, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986; 315: 1519-1524.
41. Kannisto S, Korppi M, Remes K, Voultilainen R. Serum dehydroepiandrosterone sulfate corcentration as an indicator of adnerocortical suppression in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2001; 86: 4908-4912.
42. Priftis K, Milner AD, Conway E, Honour JW. Adrenal function in asthma. Arch Dis Child 1990; 65: 838-840.
43. Littley MD, Pollock A, Kane J, Shalet SM. Basal serum dehydroepiandrosterone sulphate concentration does not predict the cortisol response to provocative testing. Ann Clin Biochem 1990; 27: 557-561.
44. Priftis K, Everard ML, Milner AD, Unexpected side-effects of inhaled steroids: a case report. Eur J Pediatr 1991; 150: 448-449.
45. Zwaan CM, Odink RJH, Delemarre-van de Waal HA, Dankert-Roelse JE, Bokma JA. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet 1992; 340: 1290-1291.
46. Drake AJ, Howells RJ, Shield JPH, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone. BMJ 2002; 3245: 1081-1082.
47. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2002; 85: 330-334.
48. Todd GRG, Acerini CL, Buck JJ et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone dipropionate. Eur Respir J 2002; 19: 1207-1209.
49. Todd GRG, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461.
50. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348: 27-29.
51. Ng PC, Folk TF, Wong GWK et at Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 1998; 83: 2390-2393.
52. Price J, Lenney W, Duncan C et al. HPA-axis effects of nebulised fluticasone propionate compared with oral prednisolone in childhood asthma. Respir Med 2002; 96: 625-631.
53. Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol 2002; 33: 208-220.
54. Hindmarsh P. Commentary: Exogenous glucocorticoids influence adrenal function, but assessment can be difficult. BMJ 2002; 324: 1083.
55. Harrison BDW, Rees LH, Cayton RM, Nabarro JDN. Recovery of hypothalamo-pituitary-adrenal function in asthmatics whose oral steroids have been stopped or reduced. Clin Endocrinol 1982; 17: 109-118.
56. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
57. Oelkers O. Adrenal Insufficiency. N Engl J Med 1996; 335: 1206-1212.
58. Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 μg day. Eur Respir J 1996; 9: 2263-2272.
59. Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics 2002; 109: 217-221.
60. Fitzgerald D, van Asperen P, Mellis C, Honner M, Smith L, Ambler G. Fluticasone propionate 750 μg/day versus beclomethasone dipropionate 1500 μg/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax 1998; 52: 656-661.
61. Ninan TK, Reid IW, Carter PF, Smail PJ, Russell G. Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma. Thorax 1993; 48: 599-602.
62. Shah H, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ 1992; 304: 173-174.
63. Stewart PM, Seckl JR, Corrie J, Edwards CRW, Padfield PL. A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet 1988; i: 1208-1210.
64. Crowley S, Hindmarsh PC, Holownia P, Honour JW, Brook CGD. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol 1991; 130: 475-479.
65. Broide J, Soferman R, Kivity S, Golander A, Dickstein G, Spirer Z, Weisman Y. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995; 80: 1243-1246.
66. Kannisto S, Korppi M, Remes K, Voultainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000; 85: 652-657.
67. Schlaghecke R, Kornely F, Santen RT, Ridderskamip P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326: 226-230.
68. Clark DJ, Lipworth BJ. Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients. Chest 1997; 112: 1248-1252.
69. Nerwick PG, Braatvedt G, Hancock J, Corrall RJM. Self-management of adrenal insufficiency by rectal hydrocortisone. Lancet 1990; 335: 212-213.
70. Pedersen S, Steffensen G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Pharmacol 1993; 36: 2111-2114.